Last reviewed · How we verify
SB012
At a glance
| Generic name | SB012 |
|---|---|
| Also known as | Active drug substance is hgd40 |
| Sponsor | Sterna Biologicals GmbH & Co. KG |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Efficacy, Pharmacokinetics, Tolerability, Safety of SB012 Intrarectally Applied in Active Ulcerative Colitis Patients (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SB012 CI brief — competitive landscape report
- SB012 updates RSS · CI watch RSS
- Sterna Biologicals GmbH & Co. KG portfolio CI